These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 16183706)

  • 1. TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for alpha2- and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates.
    Atack JR; Wafford KA; Tye SJ; Cook SM; Sohal B; Pike A; Sur C; Melillo D; Bristow L; Bromidge F; Ragan I; Kerby J; Street L; Carling R; Castro JL; Whiting P; Dawson GR; McKernan RM
    J Pharmacol Exp Ther; 2006 Jan; 316(1):410-22. PubMed ID: 16183706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benzodiazepine binding site occupancy by the novel GABAA receptor subtype-selective drug 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in rats, primates, and humans.
    Atack JR; Wong DF; Fryer TD; Ryan C; Sanabria S; Zhou Y; Dannals RF; Eng WS; Gibson RE; Burns HD; Vega JM; Vessy L; Scott-Stevens P; Beech JS; Baron JC; Sohal B; Schrag ML; Aigbirhio FI; McKernan RM; Hargreaves RJ
    J Pharmacol Exp Ther; 2010 Jan; 332(1):17-25. PubMed ID: 19779131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine: a functionally selective gamma-aminobutyric acid(A) (GABA(A)) alpha2/alpha3-subtype selective agonist that exhibits potent anxiolytic activity but is not sedating in animal models.
    Carling RW; Madin A; Guiblin A; Russell MG; Moore KW; Mitchinson A; Sohal B; Pike A; Cook SM; Ragan IC; McKernan RM; Quirk K; Ferris P; Marshall G; Thompson SA; Wafford KA; Dawson GR; Atack JR; Harrison T; Castro JL; Street LJ
    J Med Chem; 2005 Nov; 48(23):7089-92. PubMed ID: 16279764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effects of nonselective and subtype-selective gamma-aminobutyric acidA receptor positive modulators in the rat-conditioned emotional response test.
    Mathiasen LS; Rodgers RJ; Mirza NR
    Behav Pharmacol; 2007 May; 18(3):191-203. PubMed ID: 17426483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-tetrahydrobenzo[4,5]imidazo[1,2a]pyridine-4-N-(2-fluorophenyl)carboxamide (RWJ-51204), a new nonbenzodiazepine anxiolytic.
    Dubinsky B; Vaidya AH; Rosenthal DI; Hochman C; Crooke JJ; DeLuca S; DeVine A; Cheo-Isaacs CT; Carter AR; Jordan AD; Reitz AB; Shank RP
    J Pharmacol Exp Ther; 2002 Nov; 303(2):777-90. PubMed ID: 12388665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing abuse liability of GABAA/benzodiazepine ligands via selective partial agonist efficacy at alpha1 and alpha2/3 subtypes.
    Ator NA; Atack JR; Hargreaves RJ; Burns HD; Dawson GR
    J Pharmacol Exp Ther; 2010 Jan; 332(1):4-16. PubMed ID: 19789360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SL651498: an anxioselective compound with functional selectivity for alpha2- and alpha3-containing gamma-aminobutyric acid(A) (GABA(A)) receptors.
    Griebel G; Perrault G; Simiand J; Cohen C; Granger P; Decobert M; Françon D; Avenet P; Depoortere H; Tan S; Oblin A; Schoemaker H; Evanno Y; Sevrin M; George P; Scatton B
    J Pharmacol Exp Ther; 2001 Aug; 298(2):753-68. PubMed ID: 11454940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonist.
    Atack JR; Maubach KA; Wafford KA; O'Connor D; Rodrigues AD; Evans DC; Tattersall FD; Chambers MS; MacLeod AM; Eng WS; Ryan C; Hostetler E; Sanabria SM; Gibson RE; Krause S; Burns HD; Hargreaves RJ; Agrawal NG; McKernan RM; Murphy MG; Gingrich K; Dawson GR; Musson DG; Petty KJ
    J Pharmacol Exp Ther; 2009 Nov; 331(2):470-84. PubMed ID: 19704033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative cue generalization profiles of L-838, 417, SL651498, zolpidem, CL218,872, ocinaplon, bretazenil, zopiclone, and various benzodiazepines in chlordiazepoxide and zolpidem drug discrimination.
    Mirza NR; Rodgers RJ; Mathiasen LS
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1291-9. PubMed ID: 16339395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of ketamine-induced working memory impairments by the GABAAalpha2/3 agonist TPA023.
    Castner SA; Arriza JL; Roberts JC; Mrzljak L; Christian EP; Williams GV
    Biol Psychiatry; 2010 May; 67(10):998-1001. PubMed ID: 20189164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism and disposition of a potent and selective GABA-Aalpha2/3 receptor agonist in healthy male volunteers.
    Polsky-Fisher SL; Vickers S; Cui D; Subramanian R; Arison BH; Agrawal NG; Goel TV; Vessey LK; Murphy MG; Lasseter KC; Simpson RC; Vega JM; Rodrigues AD
    Drug Metab Dispos; 2006 Jun; 34(6):1004-11. PubMed ID: 16510541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subtype-selective GABA(A) receptor modulation yields a novel pharmacological profile: the design and development of TPA023.
    Atack JR
    Adv Pharmacol; 2009; 57():137-85. PubMed ID: 20230761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GABA A receptor subtype selectivity underlying selective anxiolytic effect of baicalin.
    Wang F; Xu Z; Ren L; Tsang SY; Xue H
    Neuropharmacology; 2008 Dec; 55(7):1231-7. PubMed ID: 18723037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GABAA receptor alpha2/alpha3 subtype-selective modulators as potential nonsedating anxiolytics.
    Atack JR
    Curr Top Behav Neurosci; 2010; 2():331-60. PubMed ID: 21309116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical and clinical pharmacology of TPA023B, a GABAA receptor α2/α3 subtype-selective partial agonist.
    Atack JR; Hallett DJ; Tye S; Wafford KA; Ryan C; Sanabria-Bohórquez SM; Eng WS; Gibson RE; Burns HD; Dawson GR; Carling RW; Street LJ; Pike A; De Lepeleire I; Van Laere K; Bormans G; de Hoon JN; Van Hecken A; McKernan RM; Murphy MG; Hargreaves RJ
    J Psychopharmacol; 2011 Mar; 25(3):329-44. PubMed ID: 20156926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers.
    de Haas SL; de Visser SJ; van der Post JP; de Smet M; Schoemaker RC; Rijnbeek B; Cohen AF; Vega JM; Agrawal NG; Goel TV; Simpson RC; Pearson LK; Li S; Hesney M; Murphy MG; van Gerven JM
    J Psychopharmacol; 2007 Jun; 21(4):374-83. PubMed ID: 17092968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The in vivo properties of pagoclone in rat are most likely mediated by 5'-hydroxy pagoclone.
    Atack JR; Pike A; Marshall G; Stanley J; Lincoln R; Cook SM; Lewis RT; Blackaby WP; Goodacre SC; McKernan RM; Dawson GR; Wafford KA; Reynolds DS
    Neuropharmacology; 2006 May; 50(6):677-89. PubMed ID: 16430927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discriminative stimulus effects of L-838,417 (7-tert-butyl-3-(2,5-difluoro-phenyl)-6-(2-methyl-2H-[1,2,4]triazol-3-ylmethoxy)-[1,2,4]triazolo[4,3-b]pyridazine): role of GABA(A) receptor subtypes.
    Licata SC; Platt DM; Rüedi-Bettschen D; Atack JR; Dawson GR; Van Linn ML; Cook JM; Rowlett JK
    Neuropharmacology; 2010 Feb; 58(2):357-64. PubMed ID: 19853619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for alpha5-containing GABAA receptors.
    Atack JR; Bayley PJ; Seabrook GR; Wafford KA; McKernan RM; Dawson GR
    Neuropharmacology; 2006 Nov; 51(6):1023-9. PubMed ID: 17046030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted deletion of the GABRA2 gene encoding alpha2-subunits of GABA(A) receptors facilitates performance of a conditioned emotional response, and abolishes anxiolytic effects of benzodiazepines and barbiturates.
    Dixon CI; Rosahl TW; Stephens DN
    Pharmacol Biochem Behav; 2008 Jul; 90(1):1-8. PubMed ID: 18313124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.